NYSE - Nasdaq Real Time Price ? USD Bausch + Lomb Corporation (BLCO) Follow Compare 20.46 +0.28 (+1.39%) At close: October 25 at 4:00 PM EDT 20.63 +0.17 (+0.83%) After hours: October 25 at 7:38 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Bausch + Lomb price target raised to $23 from $20 at RBC Capital RBC Capital analyst Douglas Miehm raised the firm’s price target on Bausch + Lomb (BLCO) to $23 from $20 and keeps an Outperform rating on the shares ahead of its Q3 results. The firm is incorporating a sale scenario into its new price target with several media articles over the last month indicating that the company is working with advisers to test interest from potential buyers, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, marke TipRanks ? 3 days ago BLCO +1.39% Bausch + Lomb Receives FDA Approval for enVista? Envy? Full Range of Vision Intraocular Lens VAUGHAN, Ontario, October 14, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista? Envy? full range of vision intraocular lens (IOL), which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. Business Wire ? 13 days ago BLCO +1.39% Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 VAUGHAN, Ontario, October 09, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the star Business Wire ? 18 days ago BLCO +1.39% Bausch + Lomb price target raised to $19 from $17 at Evercore ISI Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q TipRanks ? 25 days ago BLCO +1.39% Bausch + Lomb Launches Opal? Digital Marketplace in the United States VAUGHAN, Ontario, October 01, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize efficiencies for eye care practices while enhancing the patient experience, Opal provides a streamlined ordering process for Bausch + Lomb contact lenses, with select Bausch + Lomb over-the-counter products to be added in the co Business Wire ? 26 days ago BLCO +1.39% Stocks to Watch Monday: DJT, Apple, Pfizer, Intel **↗?** **Trump Media & Technology Group (DJT)**: Shares of Truth Social's parent company were volatile Monday, recently standing about 2.6% lower. On Sunday, Donald Trump was the target of a second apparent assassination attempt. The Wall Street Journal ? last month INTC BLCO +1.39% PFE Bausch + Lomb explores sale amid parent company's debt woes - report Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with significant debt, as per a Financial Times report. The move has faced opposition from lenders, including Apollo Global Management (NYSE:APO). “This (sale) makes sense to us given the steep valuation discount between BLCO and its closest eye care peers,” said analysts from Wells Fargo in a note. Investing.com ? last month BHC -0.99% BLCO +1.39% Bausch + Lomb Insider Ups Holding During Year From what we can see, insiders were net buyers in Bausch + Lomb Corporation's ( NYSE:BLCO ) during the past 12 months... Simply Wall St. ? 2 months ago BLCO +1.39% Insider Buying: CEO Brent Saunders Acquires Shares of Bausch & Lomb Corp The transaction was filed with the SEC and indicates a strong signal of confidence from the insider. Following this acquisition, the insider now owns 627,419 shares of Bausch & Lomb Corp. Bausch & Lomb Corp is primarily engaged in the development, manufacture, and marketing of a range of pharmaceutical, medical device, and over-the-counter products, particularly in eye health. GuruFocus.com ? 2 months ago BLCO +1.39% Bausch + Lomb Announces Second-Quarter 2024 Results VAUGHAN, Ontario, July 31, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2024 financial results. Business Wire ? 2 months ago BLCO +1.39% Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31 VAUGHAN, Ontario, July 11, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of Business Wire ? 3 months ago BLCO +1.39% Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief VAUGHAN, Ontario, July 08, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today shared results from the company’s inaugural State of Dry Eye survey, which explores dry eye understanding and experiences among American adults. Dry eye is increasingly common and can range from occasional symptoms of dryness to a chronic condition called dry eye disease. Although there is no cure for dry eye, there are vari Business Wire ? 3 months ago BLCO +1.39% Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress VAUGHAN, Ontario, June 17, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22. Business Wire ? 4 months ago BLCO +1.39% Bausch + Lomb INFUSE? for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States VAUGHAN, Ontario, June 10, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology? and the company’s proprietary OpticAlign? design, INFUSE for Astigmatism provides astigmatic patients clear, stable vision, all-day comfo Business Wire ? 4 months ago BLCO +1.39% Bausch + Lomb Launches Blink? NutriTears? Clinically Proven Nutritional Supplement for Dry Eyes in the United States VAUGHAN, Ontario, June 03, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes healthy tear production and provides noticeable relief of eye dryness symptoms in as little as two to four weeks.1,2* Business Wire ? 4 months ago BLCO +1.39% Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results VAUGHAN, Ontario, May 29, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the "Annual Meeting") held on May 29, 2024. The detailed results of the vote for the election of directors are set out below: Business Wire ? 4 months ago BLCO +1.39% Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting? VAUGHAN, Ontario, May 28, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Association (AOA) Optometry’s Meeting ePoster Session, taking place virtually May 29-30, 2024. The company will also have three live presentations and host nine education events during the in-person meeting, taking place in Nashville June 19-22, 2024. Business Wire ? 4 months ago BLCO +1.39% Bausch + Lomb Receives Health Canada Approval for enVista? Envy?* Full Visual Range Intraocular Lens VAUGHAN, Ontario, May 28, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista? Envy?* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. Business Wire ? 4 months ago BLCO +1.39% Bausch + Lomb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags Bausch + Lomb ( NYSE:BLCO ) First Quarter 2024 Results Key Financial Results Revenue: US$1.10b (up 18% from 1Q 2023... Simply Wall St. ? 5 months ago BLCO +1.39% Bausch & Lomb Corp (BLCO) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Net Loss Widening Comprehensive Analysis of Bausch & Lomb's First Quarter Financial Performance GuruFocus.com ? 5 months ago BLCO +1.39% Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return BLCO S&P/TSX Composite index YTD +19.93% +16.72% 1-Year +22.51% +28.85% 3-Year +10.59% +18.56%
